Creative Medical Technology Holdings (CELZ) Common Equity (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Common Equity of $6.1 million for Q1 2026, down 24.21% year-over-year from $8.1 million in Q1 2025, and down 18.81% quarter-over-quarter from $7.5 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) Common Equity (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Common Equity for 17 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 24.21% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (down 24.21% YoY), while the FY2025 annual figure was $7.5 million, up 18.66% from the prior year.
- Common Equity slipped to $6.1 million in Q1 2026 per CELZ's latest filing, from $7.5 million in the prior quarter.
- Across five years, Common Equity topped out at $23.0 million in Q2 2022 and bottomed at $5.6 million in Q3 2025.
- Historically, Common Equity has averaged $10.9 million across 5 years, with a median of $9.2 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity surged 6174.45% — and 2024, when it sank 45.78%.
- Creative Medical Technology Holdings' Common Equity stood at $15.9 million in 2022, then sank by 34.8% to $10.3 million in 2023, then plunged by 38.69% to $6.3 million in 2024, then grew by 18.66% to $7.5 million in 2025, then fell by 18.81% to $6.1 million in 2026.
- Business Quant data shows CELZ's Common Equity at $6.1 million in Q1 2026, $7.5 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | 8.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.68 Mn |
| Mar 31, 2026 | 6.11 Mn |
| Dec 31, 2025 | 7.52 Mn |
| Sep 30, 2025 | 5.59 Mn |
| Jun 30, 2025 | 6.83 Mn |
| Mar 31, 2025 | 8.06 Mn |
| Dec 31, 2024 | 6.34 Mn |
| Sep 30, 2024 | 6.56 Mn |
| Jun 30, 2024 | 7.61 Mn |
| Mar 31, 2024 | 9.23 Mn |
| Dec 31, 2023 | 10.34 Mn |
| Sep 30, 2023 | 12.09 Mn |
| Jun 30, 2023 | 13.73 Mn |
| Mar 31, 2023 | 14.82 Mn |
| Dec 31, 2022 | 15.86 Mn |
| Sep 30, 2022 | 22.07 Mn |
| Jun 30, 2022 | 23.04 Mn |
| Mar 31, 2022 | 9.35 Mn |
| Dec 31, 2021 | 10.22 Mn |
| Sep 30, 2021 | -363,345.00 |